Hunan Hansen Pharmaceutical Co., Ltd. Stock

Equities

002412

CNE100000PK2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-17 pm EDT 5-day change 1st Jan Change
5.47 CNY +1.30% Intraday chart for Hunan Hansen Pharmaceutical Co., Ltd. -0.18% -19.32%
Sales 2022 916M 126M Sales 2023 956M 132M Capitalization 3.41B 470M
Net income 2022 168M 23.15M Net income 2023 205M 28.25M EV / Sales 2022 3.19 x
Net cash position 2022 161M 22.2M Net cash position 2023 160M 22.03M EV / Sales 2023 3.4 x
P/E ratio 2022
18.4 x
P/E ratio 2023
16.6 x
Employees 1,536
Yield 2022
4.89%
Yield 2023
-
Free-Float 46.71%
More Fundamentals * Assessed data
Dynamic Chart
Hunan Hansen Pharmaceutical's Gets Nod to Make Changes to Iopamidol Injection MT
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hansen Pharmaceutical Gets Nod to Amend Information for Isoniazid Tablets MT
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Announces Board Appointments CI
Hansen Pharma's Iohexol Injection Passes Drug Regulator's Evaluation MT
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hansen Health Industry Co., Ltd. announced that it expects to receive CNY 40 million in funding from Hunan Hansen Pharmaceutical Co., Ltd. CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day+1.30%
1 week-0.18%
Current month-7.13%
1 month-9.29%
3 months-1.80%
6 months-20.72%
Current year-19.32%
More quotes
1 week
5.36
Extreme 5.36
5.58
1 month
5.19
Extreme 5.19
6.08
Current year
4.08
Extreme 4.08
7.07
1 year
4.08
Extreme 4.08
7.38
3 years
4.08
Extreme 4.08
9.58
5 years
4.08
Extreme 4.08
13.50
10 years
4.08
Extreme 4.08
23.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 08-01-19
Director of Finance/CFO 54 20-05-24
Chairman 62 20-05-24
Members of the board TitleAgeSince
Chief Executive Officer 60 08-01-19
Director/Board Member 59 20-05-18
Director/Board Member 54 08-01-19
More insiders
Date Price Change Volume
24-06-18 5.47 +1.30% 3,451,330
24-06-17 5.4 -0.92% 3,762,900
24-06-14 5.45 +0.18% 5,859,750
24-06-13 5.44 -1.98% 6,072,390
24-06-12 5.55 +1.28% 4,731,170

End-of-day quote Shenzhen S.E., June 17, 2024

More quotes
Hunan Hansen Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of traditional Chinese medicine preparations, chemical medicine and medical preparations. The Company’s main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The Company mainly distributes its products in domestic markets.
More about the company
  1. Stock Market
  2. Equities
  3. 002412 Stock